查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球 HPV 和子宫颈抹片检查检测市场（按产品/服务、检测类型、技术、应用和护理环境划分）- 预测至 2030 年
市场调查报告书
商品编码
1838144

全球 HPV 和子宫颈抹片检查检测市场（按产品/服务、检测类型、技术、应用和护理环境划分）- 预测至 2030 年

Human Papilloma Virus/HPV Test and Pap Smear/Test Market by Product & Service (Consumables, Instruments), Test Type (Follow-up, Co-testing, Primary HPV), Technology (MDx, Cytology), Application (Vaginal, Cervical), Care Setting - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 282 Pages | 订单完成后即时交付

价格

预计 2025 年全球 HPV 和子宫颈抹片检查市场价值将达到 24.4 亿美元，到 2030 年将达到 39.4 亿美元，预测期内复合年增长率为 10.0%。

人们对子宫颈癌的认识不断提高以及及时筛检的重要性正在极大地推动 HPV 和子宫颈抹片检查市场的发展。

调查范围
调查年份 2024-2030
基准年 2024
预测期 2025-2030
单元 10亿美元
部分 产品/服务、测试类型、技术、应用、护理环境
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

由于公共卫生宣传活动、政府筛检计画和教育活动的发展，女性越来越意识到HPV感染的风险以及早期检测的重要角色。这种意识的提升促使更多女性参与常规筛检项目，直接推动了HP​​V和子宫颈抹片检查的需求。医疗保健提供者、倡导团体和非营利组织的支持进一步巩固了预防性筛检作为女性医疗保健重要组成部分的地位。随着越来越多的女性能够获得筛检资讯和资源，预计筛检数量将稳定成长，从而推动市场持续成长，并加强HPV和子宫颈抹片检查在降低全球子宫颈癌发病率方面的作用。

人类乳突病毒/HPV 检测和巴氏抹片/检测市场-IMG1

“按产品/服务划分，耗材领域在 2024 年的 HPV 检测和子宫颈抹片检查市场占据主导地位。”

2024 年，耗材占据了最大的市场。这种主导地位归因于试剂、采集试剂套件和检测耗材的广泛和定期使用，它们对于 HPV 和子宫颈抹片检查检测都至关重要。子宫颈癌预防工作的不断扩大和 HPV筛检计划的日益普及正在为这些产品创造稳定的需求。耗材在确保检测结果的准确性和可重复性方面发挥关键作用，而强制要求标准化检测通讯协定的监管指南也强化了这一点。此外，越来越多地转向基于分子的 HPV 检测和自动化细胞学平台，进一步增加了对专用耗材的依赖。由于与一次性设备投资相比，耗材的使用是定期的，因此该部分是 HPV 和子宫颈抹片检查市场最大的收益驱动力。

“根据应用情况，阴道癌筛检领域预计将在预测期内实现最高增长。”

虽然子宫颈癌筛检因其高盛行率和既定的筛检指南而占据了目前筛检的大多数，但预计阴道癌筛检将在预测期内呈现最快的成长速度。这一增长主要得益于人们对阴道癌认识的提高、HPV检测诊断灵敏度的提高以及筛检范围逐渐扩大到子宫颈癌以外的领域。越来越多的研究活动和临床建议支持HPV检测用于检测多种妇科癌症，也促进了阴道癌筛检的普及。虽然阴道癌筛检目前规模相对较小，但其早期发现和改善患者预后的潜力可能会刺激需求，使阴道癌筛检成为HPV和子宫颈抹片检查市场的主要成长领域。

“预计亚太地区将成为预测期内成长最快的区域市场。”

快速的都市化、不断改善的医疗基础设施以及日益普及的诊断设施正在扩大全部区域的筛检机会。政府主导的措施和公共卫生宣传活动正在积极推动中国、印度和东南亚等国提高对子宫颈癌的认识并进行早期检测计画。 HPV 感染率的上升和人们对女性健康的日益关注推动了 HPV 和子宫颈抹片检查的普及。此外，市场参与企业正在推出根据当地需求量身定制的经济高效、高通量的检测解决方案，进一步加速了普及。医疗服务的可近性不断扩大、监管支持以及患者意识的不断提高，使亚太地区成为全球 HPV 和子宫颈抹片检查市场成长最快的区域。

本报告分析了全球 HPV 和子宫颈抹片检查市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势的资讯。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 主要发现

  • HPV 与子宫颈抹片检查市场概述
  • HPV 检测和子宫颈抹片检查市场（按产品/服务划分）（2025 年和 2030 年）
  • HPV 和子宫颈抹片检查市场（按测试类型划分）（2025 年和 2030 年）
  • HPV 和子宫颈抹片检查市场（按技术划分）（2025 年和 2030 年）
  • HPV 检测和子宫颈抹片检查市场应用（2025 年和 2030 年）
  • HPV 和子宫颈抹片检查市场（按护理环境划分）(2025 年和 2030 年)
  • HPV 与子宫颈抹片检查市场：地理成长机会

第五章 市场概况

  • 介绍
  • 市场动态
    • 驱动程式
    • 抑制因素
    • 机会
    • 任务
  • 影响客户业务的趋势/中断
  • 定价分析
    • HPV检测与子宫颈抹片检查平均售价趋势
    • 平均销售价格趋势：依主要企业划分
    • 各地区平均销售价格趋势
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 投资金筹措场景
  • 技术分析
    • 主要技术
    • 互补技术
    • 邻近技术
  • 大型会议和活动（2025-2026）
  • 专利分析
  • 贸易分析
    • HS 代码 3822 的进口数据
    • HS 代码 3822 的出口数据
  • 案例研究分析
  • 监管格局
    • 法规结构
    • 监管机构、政府机构和其他组织
  • 波特五力分析
  • 主要相关利益者和采购标准
  • 人工智慧/生成式人工智慧对HPV和子宫颈抹片检查市场的影响
    • 介绍
    • 人工智慧的市场潜力
    • 人工智慧用例
    • 采用人工智慧的主要企业
    • HPV 和子宫颈抹片检查市场中 AI 的未来
  • 2025年美国关税对HPV检测及子宫颈抹片检查市场的影响
    • 介绍
    • 主要关税税率
    • 价格影响分析
    • 对国家的影响
    • 对终端产业的影响

6. HPV检测和子宫颈抹片检查市场（依产品和服务）

  • 介绍
  • 耗材
  • 装置
  • 服务

7. HPV检测和子宫颈抹片检查市场（依检测类型）

  • 介绍
  • HPV检测
    • 初级 HPV 检测
    • 后续HPV检测
    • 联合测试
  • 子宫颈抹片检查

8. HPV检测和子宫颈抹片检查市场（依技术）

  • 介绍
  • 分子诊断
  • 免疫诊断
  • 细胞学

9. HPV检测和子宫颈抹片检查市场（依应用）

  • 介绍
  • 子宫颈癌筛检
  • 阴道癌筛检

10. HPV 检测和子宫颈抹片检查市场（依护理环境）

  • 介绍
  • 医院
  • 诊断实验室
  • 诊所

第 11 章 HPV 检测和子宫颈抹片检查市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲
    • 中东和非洲的宏观经济展望
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

第十二章 竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 收益分析（2022-2024）
  • 市占率分析（2024年）
  • 公司估值及财务指标
  • 品牌/产品比较
  • 企业评估矩阵：主要企业（2024年）
  • 公司评估矩阵：Start-Ups/中小企业（2024 年）
  • 竞争场景

第十三章：公司简介

  • 主要企业
    • HOLOGIC, INC.
    • BECTON, DICKINSON AND COMPANY (BD)
    • F. HOFFMANN-LA ROCHE LTD.
    • QIAGEN
    • DANAHER CORPORATION
    • ABBOTT
    • SEEGENE INC.
    • SD BIOSENSOR, INC.
    • SANSURE BIOTECH INC.
    • ACON LABORATORIES, INC.
  • 其他公司
    • MOLBIO DIAGNOSTICS LIMITED
    • AB ANALITICA SRL
    • CERTEST BIOTEC
    • ATILA BIOSYSTEMS
    • TELLGEN CORPORATION
    • DAAN GENE CO., LTD.
    • JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.
    • ANATOLIA GENEWORKS
    • YANENG BIOSCIENCE (SHENZHEN) CO., LTD.
    • XIAMEN ZEESAN BIOTECH CO., LTD.
    • ADVANCED MOLECULAR DIAGNOSTICS (AMD)
    • MYLAB DISCOVERY SOLUTIONS PVT. LTD.
    • SACACE BIOTECHNOLOGIES SRL
    • JIANGSU MOLE BIOSCIENCE CO., LTD.
    • HANGZHOU ALLTEST BIOTECH CO., LTD.
    • HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.
    • NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.

第十四章 附录

Product Code: MD 4083

The HPV testing and Pap test market is valued at an estimated USD 2.44 billion in 2025 and is projected to reach USD 3.94 billion by 2030, at a CAGR of 10.0% during the forecast period. The rising awareness of cervical cancer and the importance of timely screening is significantly boosting the HPV testing and Pap test market.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct & service, test type, technology, application, care setting
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Public health campaigns, government screening initiatives, and educational efforts are making women more informed about the risks associated with HPV infection and the critical role of early detection. This heightened awareness is leading to greater participation in routine screening programs, directly fueling the demand for both HPV and Pap tests. Support from healthcare providers, advocacy groups, and non-profit organizations further reinforces preventive screening as a key component of women's healthcare. As more women gain access to information and resources about screening, test volumes are expected to rise steadily, driving sustained market growth and strengthening the role of HPV and Pap testing in reducing cervical cancer incidence worldwide.

Human Papilloma Virus/HPV Test and Pap Smear/Test Market - IMG1

"By product & service, the consumables segment dominated the HPV testing and Pap test market in 2024."

Based on product & service, the HPV testing and Pap test market is segmented into consumables, instruments, and services. In 2024, consumables accounted for the largest share of the market. This dominance is driven by the widespread use of reagents, collection kits, and assay consumables that are essential for both HPV and Pap testing on a recurring basis. The increasing adoption of HPV screening programs, coupled with the expansion of cervical cancer prevention initiatives, has created steady demand for these products. Consumables play a critical role in ensuring accuracy and reproducibility of test results, which is reinforced by regulatory guidelines that mandate standardized testing protocols. Moreover, the growing shift toward molecular-based HPV assays and automated cytology platforms has further increased the reliance on specialized consumables. The recurring nature of consumable usage, compared to one-time investments in instruments, positions this segment as the largest revenue contributor in the HPV testing and Pap test market.

"By application, the vaginal cancer screening segment is projected to achieve the highest growth during the forecast period."

By application, the HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. While cervical cancer screening currently accounts for the majority of testing volumes due to its high prevalence and established screening guidelines, vaginal cancer screening is expected to witness the fastest growth during the forecast period. This growth is primarily driven by increasing awareness of vaginal cancers, improvements in diagnostic sensitivity of HPV tests, and a gradual expansion of screening practices beyond cervical cancer. Rising research efforts and clinical recommendations supporting HPV testing for broader gynecologic cancer detection are also contributing to the adoption of vaginal cancer screening. Although it remains a relatively smaller segment today, the potential for early detection and improved patient outcomes is likely to accelerate demand, positioning vaginal cancer screening as a key growth area in the HPV testing and Pap test market.

"The Asia Pacific is projected to be the fastest-growing regional market during the forecast period."

The market for HPV testing and Pap tests is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to experience the fastest growth in the HPV testing and Pap test market during the forecast period. Rapid urbanization, improving healthcare infrastructure, and increasing access to diagnostic facilities are expanding screening opportunities across the region. Government-led initiatives and public health campaigns in countries such as China, India, and Southeast Asian nations are actively promoting cervical cancer awareness and early detection programs. The rising prevalence of HPV infections and growing concerns about women's health are driving the adoption of HPV and Pap testing. Additionally, market players are introducing cost-effective and high-throughput testing solutions tailored to local needs, further accelerating adoption. The combination of expanding healthcare access, regulatory support, and rising patient awareness positions the Asia Pacific as the fastest-growing regional segment in the global HPV testing and Pap test market.

Breakdown of the profiles of primary participants in the HPV testing and Pap test market:

  • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
  • By Designation: C-level Executives (27%), Director-level Executives (18%), and Others (55%)
  • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the HPV testing and Pap test market are Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Danaher Corporation (US), Abbott (US), Seegene Inc. (South Korea), SD Biosensor, INC. (South Korea), Sansure Biotech Inc. (China), ACON Laboratories, Inc. (US), Molbio Diagnostics Limited (India), Tellgen Corporation (China), Daan Gene Co., Ltd. (China), Jiangsu BioPerfectus Technologies Co., Ltd (China), Anatolia Geneworks (Turkey), AB ANALITICA s.r.l. (Italy), CERTEST BIOTEC (Spain), Atila Biosystems (US), Yaneng BIOscience (Shenzhen) Co., Ltd. (China), Xiamen Zeesan Biotech Co., Ltd. (China), Advanced Molecular Diagnostics (AMD) (UK), Mylab Discovery Solutions Pvt. Ltd. (India), Sacace Biotechnologies Srl (Italy), Jiangsu Mole Bioscience Co., Ltd. (China), HANGZHOU ALLTEST BIOTECH CO., LTD. (China), Hangzhou Tongzhou Biotechnology Co., Ltd. (China), and Nanjing Liming Biological Products Co., Ltd. (China).

Research Coverage:

This research report categorizes the HPV testing and Pap test market by product & service (consumables, instruments, and services), test type [HPV testing (primary HPV testing, co-testing, and follow-up HPV testing) and Pap tests], technology (molecular diagnostics, immunodiagnostics, and cytology), application (cervical cancer screening and vaginal cancer screening), care setting (hospitals, diagnostic laboratories, and physicians' offices & clinics), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the HPV testing and Pap test market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. Competitive analysis of upcoming startups in the HPV testing and Pap test market ecosystem is covered in this report.

Reasons to buy this report:

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (rising HPV cases and subsequent increase in cervical cancer, growing awareness of cervical cancer screening programs, and increasing R&D funding initiatives on cervical cancer prevention), opportunities (regulatory guidelines for cervical cancer screening and innovative improvements in HPV tests), restraints (growing awareness of HPV vaccinations), and challenges (uncertain reimbursement scenario, stringent regulatory & legal requirements, and operational barriers) influencing the growth of the HPV testing and Pap test market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches/approvals in the HPV testing and Pap test market.
  • Market Development: Comprehensive information about lucrative markets across varied regions
  • Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the HPV testing and Pap test market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), and Danaher Corporation (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key secondary sources
      • 2.2.1.2 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Company revenue estimation approach
      • 2.3.1.2 Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
      • 2.3.1.5 Epidemiology-based test volume estimation approach
    • 2.3.2 TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 MARKET SHARE ASSESSMENT
  • 2.6 RESEARCH ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 HPV TESTING AND PAP TEST MARKET OVERVIEW
  • 4.2 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030
  • 4.3 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030
  • 4.4 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030
  • 4.5 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030
  • 4.6 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030
  • 4.7 HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer
      • 5.2.1.2 Growing awareness about cervical cancer screening programs
      • 5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Growing awareness and adoption of HPV vaccination
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Regulatory guidelines for cervical cancer screening
      • 5.2.3.2 Innovative improvements in HPV tests
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Uncertain reimbursement scenario
      • 5.2.4.2 Stringent regulatory and legal requirements
      • 5.2.4.3 Operational barriers
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF HPV AND PAP TESTS
    • 5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Molecular diagnostics
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Cytology
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Immunodiagnostics
  • 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.11 PATENT ANALYSIS
  • 5.12 TRADE ANALYSIS
    • 5.12.1 IMPORT DATA FOR HS CODE 3822
    • 5.12.2 EXPORT DATA FOR HS CODE 3822
  • 5.13 CASE STUDY ANALYSIS
    • 5.13.1 CASE STUDY 1: UTILIZATION OF HUMAN PAPILLOMAVIRUS TESTING FOR CERVICAL CANCER SCREENING IN THAILAND
    • 5.13.2 CASE STUDY 2: IMPLEMENTATION OF HUMAN PAPILLOMAVIRUS PRIMARY SCREENING OF CERVICAL CANCER IN BRITISH COLUMBIA
    • 5.13.3 CASE STUDY 3: COMPARATIVE EVALUATION OF HPV SELF-SAMPLING IN INDIA
  • 5.14 REGULATORY LANDSCAPE
    • 5.14.1 REGULATORY FRAMEWORK
      • 5.14.1.1 NORTH AMERICA
        • 5.14.1.1.1 US
        • 5.14.1.1.2 Canada
      • 5.14.1.2 Europe
        • 5.14.1.2.1 Germany
        • 5.14.1.2.2 UK
        • 5.14.1.2.3 France
        • 5.14.1.2.4 Italy
      • 5.14.1.3 Asia Pacific
        • 5.14.1.3.1 China
        • 5.14.1.3.2 Japan
        • 5.14.1.3.3 India
      • 5.14.1.4 Latin America
        • 5.14.1.4.1 Brazil
        • 5.14.1.4.2 Mexico
      • 5.14.1.5 Middle East
      • 5.14.1.6 Africa
    • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.15 PORTER'S FIVE FORCES ANALYSIS
    • 5.15.1 BARGAINING POWER OF BUYERS
    • 5.15.2 BARGAINING POWER OF SUPPLIERS
    • 5.15.3 THREAT OF NEW ENTRANTS
    • 5.15.4 THREAT OF SUBSTITUTES
    • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.16.2 BUYING CRITERIA
  • 5.17 IMPACT OF AI/GENERATIVE AI ON HPV TESTING AND PAP TEST MARKET
    • 5.17.1 INTRODUCTION
    • 5.17.2 MARKET POTENTIAL OF AI
    • 5.17.3 AI USE CASES
    • 5.17.4 KEY COMPANIES IMPLEMENTING AI
    • 5.17.5 FUTURE OF AI IN HPV TESTING AND PAP TEST MARKET
  • 5.18 IMPACT OF 2025 US TARIFFS ON HPV TESTING AND PAP TEST MARKET
    • 5.18.1 INTRODUCTION
    • 5.18.2 KEY TARIFF RATES
    • 5.18.3 PRICE IMPACT ANALYSIS
    • 5.18.4 IMPACT ON COUNTRY/REGION
      • 5.18.4.1 North America
      • 5.18.4.2 Europe
      • 5.18.4.3 Asia Pacific
    • 5.18.5 IMPACT ON END-USE INDUSTRIES
      • 5.18.5.1 Hospitals
      • 5.18.5.2 Diagnostic laboratories
      • 5.18.5.3 Physicians' offices & clinics

6 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    • 6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING ADOPTION OF AUTOMATED DIAGNOSTIC SYSTEMS TO DRIVE GROWTH
  • 6.4 SERVICES
    • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND

7 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
  • 7.2 HPV TESTING
    • 7.2.1 PRIMARY HPV TESTING
      • 7.2.1.1 Test sensitivity and accuracy to drive growth
    • 7.2.2 FOLLOW-UP HPV TESTING
      • 7.2.2.1 Irregular Pap test results to drive adoption
    • 7.2.3 CO-TESTING
      • 7.2.3.1 Co-testing to drive rapid detection results for cervical cancer
  • 7.3 PAP TESTS
    • 7.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET

8 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 MOLECULAR DIAGNOSTICS
    • 8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN HPV DETECTION TO DRIVE MARKET GROWTH
  • 8.3 IMMUNODIAGNOSTICS
    • 8.3.1 COST BENEFITS OF IMMUNOASSAYS TO BOOST DEMAND
  • 8.4 CYTOLOGY
    • 8.4.1 AUTOMATION AND DIGITAL IMAGING TO DRIVE ADOPTION

9 HPV TESTING AND PAP TEST MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 CERVICAL CANCER SCREENING
    • 9.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET
  • 9.3 VAGINAL CANCER SCREENING
    • 9.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET

10 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING

  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS
    • 10.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET
  • 10.3 DIAGNOSTIC LABORATORIES
    • 10.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET
  • 10.4 PHYSICIANS' OFFICES & CLINICS
    • 10.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH

11 HPV TESTING AND PAP TEST MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Rising government initiatives for cervical cancer testing to expedite growth
    • 11.2.3 CANADA
      • 11.2.3.1 Growing awareness of cervical cancer screening to support growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Established healthcare infrastructure and rising healthcare spending to promote growth
    • 11.3.3 UK
      • 11.3.3.1 Rising focus on research projects for specific cancers to contribute to growth
    • 11.3.4 FRANCE
      • 11.3.4.1 High incidence of cervical cancer and associated investments in genomics to stimulate growth
    • 11.3.5 ITALY
      • 11.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to boost market
    • 11.3.6 SPAIN
      • 11.3.6.1 Increasing research on cancer diagnostics to accelerate growth
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Growing public access to modern healthcare to propel market
    • 11.4.3 JAPAN
      • 11.4.3.1 Rising demand for technologically advanced cervical cancer screening tests to facilitate growth
    • 11.4.4 INDIA
      • 11.4.4.1 Expanding healthcare access and high cervical cancer burden to drive market
    • 11.4.5 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Universal healthcare access to speed up growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Improved access to healthcare to sustain growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 11.6.2 SAUDI ARABIA
      • 11.6.2.1 Rising government healthcare expenditure to augment growth
    • 11.6.3 UAE
      • 11.6.3.1 Increasing emphasis on healthy lifestyles and quality of life to encourage growth
    • 11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET
  • 12.3 REVENUE ANALYSIS, 2022-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
    • 12.5.1 COMPANY VALUATION
    • 12.5.2 FINANCIAL METRICS
  • 12.6 BRAND/PRODUCT COMPARISON
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.7.1 STARS
    • 12.7.2 EMERGING LEADERS
    • 12.7.3 PERVASIVE PLAYERS
    • 12.7.4 PARTICIPANTS
    • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.7.5.1 Company footprint
      • 12.7.5.2 Region footprint
      • 12.7.5.3 Product & service footprint
      • 12.7.5.4 Test type footprint
      • 12.7.5.5 Technology footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.8.1 PROGRESSIVE COMPANIES
    • 12.8.2 RESPONSIVE COMPANIES
    • 12.8.3 DYNAMIC COMPANIES
    • 12.8.4 STARTING BLOCKS
    • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.8.5.1 Detailed list of key startups/SMEs
      • 12.8.5.2 Competitive benchmarking of key startups/SMEs
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 HOLOGIC, INC.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 MnM view
        • 13.1.1.3.1 Right to win
        • 13.1.1.3.2 Strategic choices
        • 13.1.1.3.3 Weaknesses and competitive threats
    • 13.1.2 BECTON, DICKINSON AND COMPANY (BD)
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches and approvals
        • 13.1.2.3.2 Deals
        • 13.1.2.3.3 Expansions
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses and competitive threats
    • 13.1.3 F. HOFFMANN-LA ROCHE LTD.
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches and approvals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses and competitive threats
    • 13.1.4 QIAGEN
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Expansions
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses and competitive threats
    • 13.1.5 DANAHER CORPORATION
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 MnM view
        • 13.1.5.3.1 Right to win
        • 13.1.5.3.2 Strategic choices
        • 13.1.5.3.3 Weaknesses and competitive threats
    • 13.1.6 ABBOTT
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product launches and approvals
        • 13.1.6.3.2 Deals
    • 13.1.7 SEEGENE INC.
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Product launches and approvals
        • 13.1.7.3.2 Deals
    • 13.1.8 SD BIOSENSOR, INC.
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
    • 13.1.9 SANSURE BIOTECH INC.
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches and approvals
        • 13.1.9.3.2 Deals
    • 13.1.10 ACON LABORATORIES, INC.
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 MOLBIO DIAGNOSTICS LIMITED
    • 13.2.2 AB ANALITICA S.R.L.
    • 13.2.3 CERTEST BIOTEC
    • 13.2.4 ATILA BIOSYSTEMS
    • 13.2.5 TELLGEN CORPORATION
    • 13.2.6 DAAN GENE CO., LTD.
    • 13.2.7 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.
    • 13.2.8 ANATOLIA GENEWORKS
    • 13.2.9 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.
    • 13.2.10 XIAMEN ZEESAN BIOTECH CO., LTD.
    • 13.2.11 ADVANCED MOLECULAR DIAGNOSTICS (AMD)
    • 13.2.12 MYLAB DISCOVERY SOLUTIONS PVT. LTD.
    • 13.2.13 SACACE BIOTECHNOLOGIES SRL
    • 13.2.14 JIANGSU MOLE BIOSCIENCE CO., LTD.
    • 13.2.15 HANGZHOU ALLTEST BIOTECH CO., LTD.
    • 13.2.16 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.
    • 13.2.17 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 HPV TESTING AND PAP TEST MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 HPV TESTING AND PAP TEST MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 HPV TESTING AND PAP TEST MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 4 ESTIMATED NUMBER OF NEW CASES OF CERVICAL CANCER, BY REGION, 2022 VS. 2030
  • TABLE 5 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, 2023-2025 (USD)
  • TABLE 6 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, BY REGION (USD)
  • TABLE 7 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY KEY PLAYER, 2023-2025 (USD)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY REGION, 2023-2025 (USD)
  • TABLE 9 HPV TESTING AND PAP TEST MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 10 HPV TESTING AND PAP TEST MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 11 HPV TESTING AND PAP TEST MARKET: LIST OF MAJOR PATENTS, 2023-2025
  • TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 14 CLASSIFICATION OF IVD DEVICES IN EUROPE
  • TABLE 15 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 HPV TESTING AND PAP TEST MARKET: IMPACT OF PORTER'S FIVE FORCES
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 23 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 24 RECIPROCAL TARIFF RATES ADJUSTED BY US
  • TABLE 25 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 26 KEY CONSUMABLES AVAILABLE IN MARKET
  • TABLE 27 HPV TESTING AND PAP TEST CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 28 KEY INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 29 HPV TESTING AND PAP TEST INSTRUMENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 30 HPV TESTING AND PAP TEST SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 31 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 32 KEY HPV TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 33 HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 34 HPV TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 35 NORTH AMERICA: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 EUROPE: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 LATIN AMERICA: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 PRIMARY HPV TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 41 NORTH AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 EUROPE: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 LATIN AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 MIDDLE EAST & AFRICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 47 NORTH AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 EUROPE: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 LATIN AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 MIDDLE EAST & AFRICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 CO-TESTING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 53 NORTH AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 EUROPE: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 LATIN AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 MIDDLE EAST & AFRICA: CO-TESTING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 KEY PAP TESTS AVAILABLE IN MARKET
  • TABLE 59 PAP TESTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 EUROPE: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 MIDDLE EAST & AFRICA: PAP TESTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 66 KEY MOLECULAR DIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET
  • TABLE 67 HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 68 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 EUROPE: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 KEY IMMUNODIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET
  • TABLE 74 HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 75 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 EUROPE: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 86 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 87 KEY HPV TESTING AND PAP TESTS FOR CERVICAL CANCER SCREENING AVAILABLE IN MARKET
  • TABLE 88 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 KEY HPV TESTING AND PAP TESTS FOR VAGINAL CANCER SCREENING AVAILABLE IN MARKET
  • TABLE 95 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 EUROPE: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 100 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 101 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 102 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 103 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 EUROPE: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 107 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 108 HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 109 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 EUROPE: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 PROJECTED CERVICAL CANCER CASES, BY COUNTRY, 2022 VS. 2030
  • TABLE 121 HPV TESTING AND PAP TEST MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 122 TOTAL NUMBER OF HPV TESTS CONDUCTED, BY REGION, 2023-2030 (MILLION UNIT)
  • TABLE 123 TOTAL NUMBER OF PAP TESTS CONDUCTED, BY REGION, 2023-2030 (MILLION UNIT)
  • TABLE 124 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 125 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 127 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 128 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 129 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 130 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 131 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 132 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 133 US: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 134 US: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 135 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 136 US: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 137 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 138 CANADA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 139 CANADA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 140 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 141 CANADA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 142 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 EUROPE: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 144 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 145 EUROPE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 146 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 147 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 148 EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 149 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 150 GERMANY: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 151 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 152 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 153 GERMANY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 154 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 155 UK: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 156 UK: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 157 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 158 UK: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 159 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 160 FRANCE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 161 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 162 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 163 FRANCE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 164 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 165 ITALY: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 166 ITALY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 167 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 168 ITALY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 169 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 170 SPAIN: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 171 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 172 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 173 SPAIN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 174 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 175 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 176 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 177 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 178 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 180 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 187 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 188 CHINA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 189 CHINA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 190 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 191 CHINA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 192 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 JAPAN: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 194 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 195 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 196 JAPAN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 197 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 INDIA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 199 INDIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 200 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 201 INDIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 202 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 203 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 204 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 205 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 206 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 207 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 208 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 209 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 210 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 211 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 212 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 213 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 214 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 215 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 216 BRAZIL: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 217 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 218 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 219 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 220 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 221 MEXICO: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 222 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 223 MEXICO: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 224 MEXICO: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 225 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 226 REST OF LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 227 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 228 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 229 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 230 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 231 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 232 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 233 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 234 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 235 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 236 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 237 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 238 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 239 SAUDI ARABIA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 240 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 241 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 242 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 243 UAE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 244 UAE: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 245 UAE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 246 UAE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 247 UAE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 248 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 249 REST OF MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 251 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 252 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023-2030 (USD MILLION)
  • TABLE 253 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, JANUARY 2022-SEPTEMBER 2025
  • TABLE 254 HPV TESTING AND PAP TEST MARKET: DEGREE OF COMPETITION
  • TABLE 255 HPV TESTING AND PAP TEST MARKET: REGION FOOTPRINT
  • TABLE 256 HPV TESTING AND PAP TEST MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 257 HPV TESTING AND PAP TEST MARKET: TEST TYPE FOOTPRINT
  • TABLE 258 HPV TESTING AND PAP TEST MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 259 HPV TESTING AND PAP TEST MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 260 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE AND TEST TYPE
  • TABLE 261 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION
  • TABLE 262 HPV TESTING AND PAP TEST MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 263 HPV TESTING AND PAP TEST MARKET: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 264 HPV TESTING AND PAP TEST MARKET: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 265 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 266 HOLOGIC, INC.: PRODUCTS OFFERED
  • TABLE 267 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
  • TABLE 268 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
  • TABLE 269 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 270 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 271 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 272 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 273 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 274 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 275 QIAGEN: COMPANY OVERVIEW
  • TABLE 276 QIAGEN: PRODUCTS OFFERED
  • TABLE 277 QIAGEN: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 278 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 279 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 280 ABBOTT: COMPANY OVERVIEW
  • TABLE 281 ABBOTT: PRODUCTS OFFERED
  • TABLE 282 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 283 ABBOTT: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 284 SEEGENE INC.: COMPANY OVERVIEW
  • TABLE 285 SEEGENE INC.: PRODUCTS OFFERED
  • TABLE 286 SEEGENE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 287 SEEGENE INC.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 288 SD BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 289 SD BIOSENSOR, INC.: PRODUCTS OFFERED
  • TABLE 290 SANSURE BIOTECH INC.: COMPANY OVERVIEW
  • TABLE 291 SANSURE BIOTECH INC.: PRODUCTS OFFERED
  • TABLE 292 SANSURE BIOTECH INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 293 SANSURE BIOTECH INC.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 294 ACON LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 295 ACON LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 296 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW
  • TABLE 297 AB ANALITICA S.R.L.: COMPANY OVERVIEW
  • TABLE 298 CERTEST BIOTEC: COMPANY OVERVIEW
  • TABLE 299 ATILA BIOSYSTEMS: COMPANY OVERVIEW
  • TABLE 300 TELLGEN CORPORATION: COMPANY OVERVIEW
  • TABLE 301 DAAN GENE CO., LTD.: COMPANY OVERVIEW
  • TABLE 302 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.: COMPANY OVERVIEW
  • TABLE 303 ANATOLIA GENEWORKS: COMPANY OVERVIEW
  • TABLE 304 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.: COMPANY OVERVIEW
  • TABLE 305 XIAMEN ZEESAN BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 306 ADVANCED MOLECULAR DIAGNOSTICS (AMD): COMPANY OVERVIEW
  • TABLE 307 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: COMPANY OVERVIEW
  • TABLE 308 SACACE BIOTECHNOLOGIES SRL: COMPANY OVERVIEW
  • TABLE 309 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW
  • TABLE 310 HANGZHOU ALLTEST BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 311 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 312 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 HPV TESTING AND PAP TEST MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 HPV TESTING AND PAP TEST MARKET: RESEARCH DESIGN METHODOLOGY
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 KEY INDUSTRY INSIGHTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 EPIDEMIOLOGY-BASED TEST VOLUME ESTIMATION APPROACH
  • FIGURE 10 HPV TESTING AND PAP TEST MARKET: TOP-DOWN APPROACH
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 HPV TESTING AND PAP TEST MARKET: RESEARCH ASSUMPTIONS
  • FIGURE 13 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030(USD MILLION)
  • FIGURE 16 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 HPV TESTING AND PAP TEST MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 19 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET
  • FIGURE 20 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 HPV TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 22 MOLECULAR DIAGNOSTICS SEGMENT TO SHOWCASE LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 23 CERVICAL CANCER SCREENING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 24 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030
  • FIGURE 25 NORTH AMERICAN MARKET TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 26 HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN HPV TESTING AND PAP TEST MARKET
  • FIGURE 28 HPV TESTING AND PAP TEST MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 29 HPV TESTING AND PAP TEST MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 30 HPV TESTING AND PAP TEST MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 31 HPV TESTING AND PAP TEST MARKET: INVESTMENT AND FUNDING SCENARIO, 2022-2025
  • FIGURE 32 HPV TESTING AND PAP TEST MARKET: PATENT ANALYSIS, JANUARY 2015-DECEMBER 2024
  • FIGURE 33 HPV TESTING AND PAP TEST MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 35 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 36 MARKET POTENTIAL OF AI IN HPV TESTING AND PAP TEST MARKET
  • FIGURE 37 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SNAPSHOT
  • FIGURE 38 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET SNAPSHOT
  • FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, 2022-2024
  • FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, 2024
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 HPV TESTING AND PAP TEST MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 44 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 45 HPV TESTING AND PAP TEST MARKET: COMPANY FOOTPRINT
  • FIGURE 46 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT
  • FIGURE 48 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
  • FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • FIGURE 50 QIAGEN: COMPANY SNAPSHOT
  • FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 52 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT
  • FIGURE 54 SD BIOSENSOR, INC.: COMPANY SNAPSHOT